Zsa Zsa Weerts

Novel ileocolonic release peppermint oil 135 6 References 1. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012;367:1626-1635. 2. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112:2120-2137. 3. Khanna R, MacDonald J, Levesque B. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 2014;48: 505-512. 4. Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. The Cochrane database of systematic reviews. 2011; DOI 10.1002/14651858.CD003460.pub3 , CD003460. 5. Enck P, Junne F, Klosterhalfen S, et al. Therapy options in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2010;22:1402-1411. 6. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109 Suppl 1:S2-26; quiz S27. 7. Chumpitazi B, Kearns G, Shulman R. Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders. Aliment Pharmacol Ther 2018;DOI 10.1111/apt.14519. 8. Hawthorn M, Ferrante J, Luchowski E, et al. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther 1988;2:101-118. 9. Grigoleit HG, Grigoleit P. Pharmacology and preclinical pharmacokinetics of peppermint oil. Phytomedicine 2005;12: 612-616. 10. Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol 2003;56:362-369. 11. Harrington A, Hughes P, Martin C, et al. A novel role for TRPM8 in visceral afferent function. Pain 2011;152:1459-1468. 12. Blackshaw LA. Transient receptor potential cation channels in visceral sensory pathways. Br J Pharmacol 2014;171:2528-2536. 13. Akbar A, Yiangou Y, Facer P, et al. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008;57:923-929. 14. Zhou Q, Yang L, Larson S, et al. Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1. Gut 2016;65:797-805. 15. Walstab J, Wohlfarth C, Hovius R, et al. Natural compounds boldine and menthol are antagonists of human 5-HT3 receptors: implications for treating gastrointestinal disorders. Neurogastroenterol Motil 2014;26(6):810-820. 16. Trombetta D, Castelli F, Sarpietro M, et al. Mechanisms of antibacterial action of three monoterpenes. Antimicrob Agents Chemother 2005;49:2474-2478. 17. Hawrelak JA, Cattley T, Myers SP. Essential oils in the treatment of intestinal dysbiosis: A preliminary in vitro study. Altern Med Rev 2009;14:380-384. 18. Harries N, James KC, Pugh WK. Antifoaming and carminative actions of volatile oils. J Clin Pharm Ther 1977;2:171-177. 19. White D, Thompson S, Wilson C, et al. A pharmacokinetic comparison of two delayed- release peppermint oil preparations, Colpermin and Mintec, for treatment of the irritable bowel syndrome. Int J Pharm 1987;40:151-155. 20. Cash B, Epstein M, Shah S. A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. Dig Dis Sci 2016; 61:560-571. 21. Mosaffa-Jahromi M, Lankarani K, Pasalar M, et al. Efficacy and safety of enteric coated capsules of anise oil to treat irritable bowel syndrome. J Ethnopharmacol 2016;194;937- 946. 22. Merat S, Khalili S, Mostajabi P, et al. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci 2010;55:1385-1390. 23. Cappello G, Spezzaferro M, Grossi L, et al. Peppermint oil (Mintoil) in the treatment of